AUS
NZ
UK
CA
USA
IND
Highlights
AstraZeneca LON:AZN posts strong interim results amid rising oncology and cardiovascular drug
Hemogenyx Pharmaceuticals LON:HEMO continues clinical progress with CEO-backed fundraising
First Development Resources LON:FDR joins FTSE AIM UK 50 INDEX, backed by Power Metal LON:POW
AstraZeneca (LON:AZN), a leading constituent of the FTSE 100, delivered robust interim earnings driven by strong in its oncology, cardiovascular, and renal segments. The company reported continued pipeline strength and operational efficiency, with management citing consistent momentum. There has also been speculation surrounding a possible move away from London markets, as AZN seeks revaluation on overseas exchanges.
Hemogenyx Pharmaceuticals (LON:HEMO), part of the FTSE AIM 100 Index, reported a capital raise through a share allotment to its CEO. The funds are being deployed to support its ongoing Phase I clinical trial for its HG-CT-1 therapy, designed for relapsed/refractory acute myeloid leukaemia. Early safety data has shown encouraging signs, reinforcing clinical development timelines.
Resources & Exploration Activity on FTSE AIM UK 50 INDEX
Power Metal Resources (LON:POW), a diversified exploration group on the FTSE AIM UK 50 INDEX, announced that First Development Resources (LON:FDR) began trading on AIM. The listing was accompanied by a capital raise and significant ownership retained by Power Metal. FDR’s portfolio includes projects with critical minerals exposure, and expectations are aligned with replicating previous spin-offs like GMET (LON:GMET).
Bezant Resources (LON:BZT), active in copper-gold projects, acknowledged a strategic partnership involving Blackstone Minerals and KCA Site Services. The collaboration involves acquiring advanced drilling equipment to accelerate the Mankayan project in the Philippines. With metal prices playing a pivotal role recently, focus remains on development momentum at this site.
Mining & Metals Updates in FTSE AIM 100 Index
Greatland Gold (LON:GGP), a gold-copper producer now listed on the ASX and part of the FTSE AIM 100 Index, released its June quarter report. The company emphasized a transformational year, marked by key milestones including expanded exploration and steady development output.
Other Notable Mentions
Premier African Minerals (LON:PR1) continues to attract interest as it progresses lithium operations in Zimbabwe. Ethernity Networks (LON:EPP), focused on data processing and networking, remains active within the small-cap tech sphere. Jet2 (LON:JET2), a prominent name in the travel sector, maintains focus on capacity and demand metrics as part of its operational strategy.
Filtronic (LON:FTC), involved in RF technology and telecom hardware, remains engaged with next-gen broadband expansion, while Barclays (LON:BARC), a core component of the FTSE 100, continues operational alignment in retail and investment banking segments.
What is the significance of FDR’s listing on AIM?
FDR's AIM debut offers enhanced visibility for its exploration assets and allows capital market access under the guidance of Power Metal.
Why is Hemogenyx raising funds again?
Funds are allocated to support its clinical development pipeline, especially ongoing trials for its HG-CT-1 cell therapy.
Is AstraZeneca planning to move its listing?
While no official confirmation has been made, discussions have surfaced regarding a move to a US exchange for valuation advantages.
